Key Highlights

  • Capricor Therapeutics shares closed up 58% at $6.65.
  • The FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy.
  • The move may push back the August 22 PDUFA deadline.
  • The update significantly reduces immediate regulatory hurdles for the lead candidate.

Capricor Therapeutics (NASDAQ: CAPR) shares closed up 58% at $6.65 following news that the FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy.

What Happened

The move may push back the August 22 PDUFA deadline while significantly reducing immediate regulatory hurdles and clarifying the path forward for the company's lead candidate.

Market Reaction

Shares surged sharply as investors responded to the reduced regulatory uncertainty, viewing the FDA's willingness to evaluate supplemental efficacy data as a constructive signal for deramiocel's approval prospects even if it delays the original PDUFA timeline.

Outlook

The revised PDUFA timeline, once confirmed, along with the FDA's ultimate decision on deramiocel for Duchenne muscular dystrophy, represent the next major disclosed milestones for Capricor Therapeutics.